The global hyperkalemia treatment market is witnessing rapid growth, driven by an increasing prevalence of chronic diseases such as diabetes and kidney failure. These conditions can lead to elevated potassium levels in the blood, known as hyperkalemia. The market is further fueled by factors like an aging population, rising healthcare expenditure,